

Edwards & Angell LLP101 Federal Street Boston, MA 02110 617.439.4444 fax 617.439.4170
www.EdwardsAngell.com**RECEIVED
CENTRAL FAX CENTER**

APR 07 2005

Date : 04/07/05

Pages (including cover) : 2

Sender :Name Peter C. Lauro
Fax 617-439-4170
Email plauro@EdwardsAngell.com

Phone 617-517-5509

To :

Name	Company	Fax	Phone
Examiner M. Rao	U.S. PTO	571-273-0939	571-272-0939

If you experience problems receiving this fax, please call Terri Lauro at 617-517-5592.

Message : U.S. Ser. No. 09/885,297; Atty. Docket No.: 49950-59776

Dear Examiner:

Further to the voice mail message I left earlier this afternoon, enclosed are some proposed claims for the purpose of discussing the issue of "derived from *Erwinia*" as recited in claim 44 which is currently pending

Again, I apologize for missing our telephone appointment this morning, and look forward to speaking with you at your earliest convenience.

Peter C. Lauro, Esq.

email: plauro@EdwardsAngell.com
Website: www.EdwardsAngell.comDirect Phone: (617)517-5509
Direct Fax: 888-325-9044
General Phone: (617)439-4444
General Fax: (617)439-4170**Fax**

Confidentiality Note : The documents accompanying this facsimile contain information from the law firm of Edwards & Angell LLP, which may be confidential and/or privileged. The information is intended only for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this facsimile is strictly prohibited, and that the documents should be returned to this firm immediately. If you have received this facsimile in error, please notify us by telephone immediately so that we can arrange for the return of the original documents to us at no cost to you.

U.S. Ser. No. 09/885,297

FOR DISCUSSION PURPOSES ONLY

44. (Currently Amended) A recombinant host cell suitable for degrading an oligosaccharide comprising:

a first heterologous polynucleotide segment encoding a first endoglucanase having a first degrading activity, wherein said segment is under the transcriptional control of a surrogate promoter; and

a second heterologous polynucleotide segment encoding a second endoglucanase having a second degrading activity, wherein said segment is under the transcriptional control of a surrogate promoter, and

a polynucleotide segment expressing an additional enzyme,

wherein said first endoglucanase and said second endoglucanase are expressed so that said first and said second degrading activities are present in a ratio such that the degrading of said oligosaccharide by said first and second endoglucanases is synergized

and wherein said first endoglucanase is encoded by *celZ* and said second endoglucanase is encoded by *celY*, and wherein *celZ* and *celY* ~~are derived~~ comprise a polynucleotide segment isolated in whole or in part from *Erwinia*.

60. (New) The recombinant host cell of claim 44, wherein said first and second endoglucanases comprise a polypeptide purified from *Erwinia*.

61. (New) The recombinant host cell of claim 44, wherein said *celZ* and *celY* comprise a polynucleotide segment prepared by a process selected from the group consisting of direct cloning of a polynucleotide sequence isolated in whole or in part from *Erwinia*, PCR amplification of a polynucleotide sequence isolated in whole or in part from *Erwinia* and artificial synthesis from or based on a polynucleotide sequence isolated in whole or in part from *Erwinia*.